Award
National Institute on Aging 5R01AG075122-05
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
Recipient
University of Arizona, Tucson, AZ, United States
Award Amount
$1,353,297.00
Ceiling
$1,353,297.00
Awarded
May 25, 2026
Identifier
5R01AG075122-05
A Phase 2 clinical trial to test PhytoSERM, a selective estrogen receptor beta modulator, for safety and efficacy in sustaining brain glucose metabolism and improving cognitive and menopausal symptoms in peri- and post-menopausal women.
Description
This project aims to evaluate the efficacy of PhytoSERM in preventing menopause-related decline in brain metabolism and cognition, with a focus on safety, cognitive function, vasomotor symptoms, sleep quality, and MRI biomarkers.